Ignite Creation Date:
2024-05-05 @ 10:22 PM
Last Modification Date:
2024-10-26 @ 10:18 AM
Study NCT ID:
NCT01096069
Status:
UNKNOWN
Last Update Posted:
2010-03-30
First Post:
2010-02-23
Brief Title:
Complement Regulatory Proteins Expression and Clinical Response in Rheumatoid Arthritis RA Patients Treated With Rituximab
Sponsor:
Hospital de Clinicas de Porto Alegre
Organization:
Hospital de Clinicas de Porto Alegre
Study Overview
Official Title:
Expressão de Cregs e a Resposta clínica em Pacientes AR Tratada Com Rituximabe
Status:
UNKNOWN
Status Verified Date:
2010-03
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
There is a correlation between the CD55 CD59 CD35 and CD46 expression on B lymphocytes of patients before and after treatment with rituximab and the level of depletion and repopulation time for these cells The theoretical rationale of the study assumes that the correlation if any will be a negative correlation However the hypothesis of positive correlation two-tailed test will also be tested
Detailed Description:
Rituximab an anti-CD20 monoclonal antibody is a new alternative treatment for patients with severe immune diseases and resistance to conventional treatment One of the mechanisms of action of this drug is the complement-mediated lysis Most RA patients respond well to rituximab treatment however some are refractory and mechanism of this non-response is still unclear The role of CD55 and CD59 protein and its overexpression as a mechanism of resistance to rituximab treatment in lymphoma patients have been investigated However there has not been studied a correlation between the intensity of expression of these regulatory molecules on B cells of RA patients and resistance to treatment with Rituximab
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None